TABLE 2.
Characteristics of Patients in the Included Studies
| First Author | Medication | Total Number of Patients in Treatment Arm | Median Age (Years) | Age Range (Years) | Gender (% Male) | Median Duration of Follow-up (Months) | Median Duration Until Mutation Detected (Months) | CML Phase (at Time of Study Entry) |
|---|---|---|---|---|---|---|---|---|
| Radich, J17 | Imatinib | 13 | 50 | 19-89 | 59 | 36 | NR | CP |
| Dasatinib | 9 | 47 | 18-90 | 60 | 36 | NR | ||
| Soverini, S38 | Imatinib | 175 | 53 | 29-68 | 55.6 | 32.5 | 3 | CP |
| Branford, S39 | Imatinib | 53 | NR | NR | NR | 33 | NR | CP |
| Branford, S30 | Imatinib | 144 | NR | NR | NR | NR | 8 | AP (40), late-CP (64), early-CP (44) |
| de Lavallade, H40 | Imatinib | 192 | 46.3 | 18-79 | 56.9 | 38 | 10.5 | CP |
| He, H20 | Imatinib | 210, 24, 41 | NR | 16-80 | 56.7 | 48, 40, 17 | 14.6 | CP (76), AP (9), BC (15) |
| Kantarjian, H16 | Imatinib | 258 | 49 | 18-78 | 63 | 26.7 | NR | CP |
| Dasatinib | 258 | 46 | 18-84 | 56 | 26.5 | NR | CP | |
| Roche-Lestienne, C13 | Imatinib | 71 | NR | NR | NR | NR | 3 | CP (67), AP (33) |
| Elnahass, Y33 | Imatinib | 72 | 42 | 18-72 | 61.1 | 41.6 | NR | CP |
| Wei, Y41 | Imatinib | 40 | NR | 23-80 | 52.5 | 24 | 10.5 | CP (92), AP (8) |
| Cortes, J19 | Nilotinib | 61 | 46 | 19-86 | NR | 17.3 | NR | early CP |
| Cortes, J18 | Dasatinib | 62 | 47 | 18-76 | NR | 24 | NR | CP |
AP = accelerated phase; BC = blast crisis; CML = chronic myeloid leukemia; CP = chronic phase; NR = not reported.